Su questa pagina
NKTR Nektar Therapeutics - Common Stock
NASDAQ · Pharmaceuticals · Visualizza su SEC EDGAR ↗ chiudi Ott 2, 2026 10-K/10-Q Ago 14, 2026
$43,58
· % dell'intervallo 52 sett.
· sopra il minimo
· al massimo
$33,40minimo 52 sett.
$109,00massimo 52 sett.
Capitalizzazione di Mercato (MRQ)
$888M
P/E (TTM)
-4.5
EPS (TTM)
$-9.59
Ricavi (TTM)
$55M
i tuoi badge
Intervallo 52 sett.
$33–$109
Rating Analisti
BUY
Prezzo Obiettivo
$141
P/E
-4.5
ROE
-35.8%
Margine di Profitto Netto
-287.8%
La tua barra dei badge è vuota — aggiungi una metrica a piacere in questa pagina.
NKTR Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$43.58
Capitalizzazione di Mercato (MRQ)
$888M
P/E (TTM)
-4.5
EPS (TTM)
$-9.59
Ricavi (TTM)
$55M
ROE (TTM)
-35.8%
Intervallo 52 sett.
$33–$109
NKTR Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
intervallo
barre
La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.
Split azionari
| Data ex-dividendo | Split | Tipo |
|---|---|---|
| 09 Giugno 2025 | 1-for-15 | Inverso |
| 23 Agosto 2000 | 2-for-1 | Avanti |
Informazioni su Nektar Therapeutics - Common Stock Panoramica della società da Wikipedia
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.
Background
The company is engaged in developing a proprietary pipeline of drug candidates for several therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. The company's research and development involve in small molecule and biologic drug candidates. Its drug candidate base consists of naloxegol (Movantik), a Phase III oral opioid antagonist, etirinotecan pegol, a topoisomerase inhibitor under Phase III clinical study as of 2012, NKTR 061, NKTR-181, NKTR-214, etc.
In 2013, the company was assigned a patent which was developed by the company and other four co-inventors. The products of the company is served as a supplement to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability and other areas of drugs for the patients worldwide. As of March 2014, the company had a market capitalization of $1.7 billion with an enterprise value of $1.67 billion.
As of December 2024, at a stock price-per-share of roughly $1, the market cap is roughly $171 million. Nektar underwent periods of downsizing after unsuccessful partnerships were ended with Eli Lilly in 2023 and Bristol Myers Squibb in 2022, resulting in layoffs of most company employees.
Pipeline
Etirinotecan pegol was in the phase III BEACON trial as well as in the I-SPY2 adaptive clinical trial for breast cancer in 2016. The European Medicines Agency refused a marketing authorisation in 2017.
Bempegaldesleukin (NKTR-214) is a CD122-biased immune-stimulatory cytokine, Phase I results were announced in November 2016. It is now in a phase 2 trial in combination with nivolumab for various advanced cancers.
In 2023 Nektar's partnership with Eli Lilly in development of "rezpeg" was ended. Eli Lilly claimed the drug lacked suitable efficacy, while Nektar responded that Eli Lilly had botched the analysis.
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
settoreHealthcare
industriaPharmaceuticals
dipendenti63
paeseUS
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi$55M2016-12-31 → 2025-12-31
EPS$-9.732016-12-31 → 2025-12-31
Flusso di cassa libero$-209M2016-12-31 → 2025-12-31
Margine netto-287.8%2016-12-31 → 2025-12-31
Valutazione e Rapporti
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
| Metrica | Tendenza 5 anni | NKTR | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| P/E (TTM) | -4.5media 5 anni ≈-20.0 | ≈-20.0 | · | · | |
| P/S (TTM) | 16.3media 5 anni ≈99.6 | ≈99.6 | 4.5 | Sopravvalutato | |
| P/B (MRQ) | 1.0media 5 anni ≈27.5 | ≈27.5 | 7.2 | Sottovalutato | |
| Prezzo / FCF (TTM) | -3.8media 5 anni ≈-27.1 | ≈-27.1 | · | · | |
| Prezzo / Flusso di cassa (TTM) | -3.8media 5 anni ≈-27.9 | ≈-27.9 | · | · | |
| Price / Tangible Book (Prezzo / Valore contabile tangibile) | 14.3media 5 anni ≈29.8 | ≈29.8 | · | · |
La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
| Metrica | Tendenza 5 anni | NKTR | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Margine Operativo (TTM) | -257.8%media 5 anni ≈-299.9% | ≈-299.9% | -26.5% | Debole | |
| EBITDA Margin (Margine EBITDA) | -253.7%media 5 anni ≈-292.3% | ≈-292.3% | -18.9% | Debole | |
| Margine ante imposte (TTM) | -296.5%media 5 anni ≈-327.0% | ≈-327.0% | -14.3% | Debole | |
| Margine di Profitto Netto (TTM) | -287.8%media 5 anni ≈-327.6% | ≈-327.6% | -10.7% | Debole | |
| ROA (TTM) | -24.1%media 5 anni ≈-43.9% | ≈-43.9% | -12.8% | Debole | |
| ROE (TTM) | -35.8%media 5 anni ≈-214.5% | ≈-214.5% | -21.0% | Debole | |
| ROIC | -155.8%media 5 anni ≈-139.8% | ≈-139.8% | -22.1% | Debole |
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
| Metrica | Tendenza 5 anni | NKTR | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Rapporto corrente (MRQ) | 10.4media 5 anni ≈6.6 | ≈6.6 | 5.5 | Liquidità elevata | |
| Quick Ratio | 0.3media 5 anni ≈0.7 | ≈0.7 | 1.5 | Bassa liquidità |
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
| Metrica | Tendenza 5 anni | NKTR | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Revenue YoY (Ricavi YoY) | -43.9%media 5 anni ≈-16.0% | ≈-16.0% | · | · | |
| Revenue CAGR 3Y (CAGR Ricavi 3Y) | -15.7%media 5 anni ≈-11.0% | ≈-11.0% | · | · | |
| Revenue CAGR 5Y (CAGR Ricavi 5Y) | -18.4% | · | · | · |
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
| Metrica | Tendenza 5 anni | NKTR | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Asset Turnover (Rotazione delle attività) | 0.2media 5 anni ≈0.2 | ≈0.2 | 0.5 | Debole | |
| Revenue / Employee (Ricavi / Dipendente) | ≈$876.7K | · | · | · |
valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
8.3%
Prossimo report
Nov 04, 2026
| Periodo | Rapporto | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|---|
| 30 Giugno 2026 | Ago 13, 2026 | $-1.23 | $-2.02 | 39.2% |
| 31 Marzo 2026 | Mag 7, 2026 | $-1.82 | $-1.63 | -11.9% |
| 31 Dicembre 2025 | $-1.78 | $-2.52 | 29.5% | |
| 30 Settembre 2025 | $-1.87 | $-2.74 | 31.7% | |
| 30 Giugno 2025 | $-2.95 | $-3.10 | 4.7% | |
| 31 Marzo 2025 | $-3.60 | $-2.51 | -43.2% |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $55M | $98M | $90M | $92M | $102M | $153M | $115M | $1.19B | $308M | $165M | $231M | $201M | |
| Cost of Revenue | $0 | $31M | $34M | $22M | $25M | $19M | $21M | $24M | $31M | $30M | $34M | $29M | |
| R&D Expense | $117M | $121M | $114M | $218M | $400M | $409M | $435M | $400M | $268M | $204M | $183M | $148M | |
| SG&A Expense | $69M | $77M | $77M | $92M | $123M | $105M | $99M | $81M | $52M | $44M | $43M | $41M | |
| Operating Expenses | $195M | $204M | $354M | $468M | $548M | $578M | $555M | $505M | $367M | $278M | $260M | $217M | |
| Operating Income | $-140M | $-105M | $-264M | $-376M | $-446M | $-425M | $-440M | $688M | $-60M | $-113M | $-29M | $-16M | |
| Interest Expense | · | · | · | $0 | $0 | $7M | $21M | $22M | $22M | $22M | $18M | $18M | |
| Interest Income | $10M | $14M | $19M | $7M | $3M | · | · | · | · | · | · | · | |
| Other Non-op | $361.0K | $-390.0K | $-6M | $-116.0K | $-162.0K | $18M | $46M | $38M | $5M | $2M | $2M | $814.0K | |
| Pretax Income | $-164M | $-119M | $-276M | $-365M | $-523M | $-444M | $-440M | $683M | $-96M | $-153M | $-81M | $-54M | |
| Income Tax | $-138.0K | $-239.0K | $-200.0K | $3M | $557.0K | $493.0K | $613.0K | $1M | $616.0K | $876.0K | $506.0K | $-512.0K | |
| Net Income | $-164M | $-119M | $-276M | $-368M | $-524M | $-444M | $-441M | $681M | $-97M | $-154M | $-81M | $-54M | |
| EPS (Basic) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $4.02 | $-0.62 | $-1.10 | · | · | |
| EPS (Diluted) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $3.78 | $-0.62 | $-1.10 | · | · | |
| Shares (Basic) | 16,870,930 | 13,710,775 | 190,001,000 | 187,138,000 | 183,298,000 | 178,581,000 | 174,993,000 | 169,600,000 | 155,953,000 | 139,596,000 | · | · | |
| Shares (Diluted) | 16,870,930 | 13,710,775 | 190,001,000 | 187,138,000 | 183,298,000 | 178,581,000 | 174,993,000 | 180,119,000 | 155,953,000 | 139,596,000 | · | · | |
| EBITDA | $-140M | $-101M | $-257M | $-364M | $-433M | $-413M | $-429M | $697M | $-47M | $-113M | $-29M | · |
Stato Patrimoniale
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15M | $44M | $35M | $88M | $25M | $199M | $96M | $195M | $5M | $60M | $56M | $12M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $291M | $329M | $253M | $225M | |
| Receivables | · | $0 | $1M | $6M | $22M | $39M | $37M | $43M | $5M | $16M | $20M | $4M | |
| Inventory | $0 | $0 | $16M | $19M | $16M | $15M | $13M | $11M | $11M | $11M | $11M | $13M | |
| Other Current Assets | $21M | $6M | $10M | $16M | $23M | $22M | $15M | $21M | $8M | $10M | $10M | $9M | |
| Current Assets | $266M | $261M | $331M | $546M | $796M | $1.14B | $1.42B | $1.44B | $327M | $426M | $350M | $288M | |
| PP&E (Net) | $2M | $3M | $19M | $32M | $61M | $60M | $66M | $49M | $47M | $66M | $71M | $70M | |
| Accum. Depreciation | · | $16M | $87M | $125M | $148M | $138M | $128M | $121M | $115M | $111M | $103M | $94M | |
| Goodwill | · | · | $0 | $77M | $77M | $77M | $77M | $77M | $77M | $77M | $77M | $77M | |
| Other Non-current Assets | $14M | $5M | $5M | $2M | $3M | $1M | $344.0K | $4M | $994.0K | $817.0K | $754.0K | $7M | |
| Total Assets | $280M | $304M | $398M | $711M | $1.12B | $1.54B | $1.98B | $2.15B | $509M | $569M | $499M | $442M | |
| Accounts Payable | $11M | $12M | $10M | $13M | $10M | $22M | $19M | $6M | $5M | $3M | $2M | $3M | |
| Accrued Liabilities | $22M | $30M | $22M | $37M | · | · | · | · | · | · | · | $6M | |
| Current Liabilities | $54M | $61M | $51M | $68M | $85M | $116M | $354M | $82M | $56M | $72M | $61M | $64M | |
| Capital Leases | $65M | $83M | $99M | $113M | $126M | $136M | $143M | $0 | · | $2M | $1M | $4M | |
| Other Non-current Liabilities | $9M | $7M | $5M | $8M | $4M | $9M | $768.0K | $10M | $6M | $7M | $10M | $15M | |
| Total Liabilities | $191M | $243M | $267M | $344M | $438M | $461M | $572M | $433M | $421M | $481M | $492M | $405M | |
| Common Stock | $2.0K | $1.0K | $19.0K | $19.0K | $19.0K | $18.0K | $17.0K | $17.0K | $15.0K | $15.0K | $13.0K | $13.0K | |
| Retained Earnings | $-3.76B | $-3.60B | $-3.48B | $-3.20B | $-2.83B | $-2.31B | $-1.86B | $-1.42B | $-2.12B | $-2.02B | $-1.87B | $-1.79B | |
| Treasury Stock | · | $3M | $0 | · | · | · | · | · | · | · | · | · | |
| AOCI | $17.0K | $61.0K | $80.0K | $-7M | $-4M | $-2M | $-1M | $-6M | $-2M | $-2M | $-2M | $-2M | |
| Stockholders' Equity | $90M | $61M | $131M | $367M | $680M | $1.08B | $1.41B | $1.72B | $88M | $88M | $6M | $36M | |
| Liabilities + Equity | $280M | $304M | $398M | $711M | $1.12B | $1.54B | $1.98B | $2.15B | $509M | $569M | $499M | $442M | |
| Shares Outstanding | 20,378,832 | 12,385,001 | 12,757,984 | 188,560,000 | 185,468,000 | 180,091,000 | 176,505,000 | 173,530,000 | 159,524,000 | 153,212,000 | 135,289,000 | 131,216,000 |
Flusso di cassa
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $4M | $7M | $12M | $13M | $12M | $11M | $9M | $13M | $13M | $11M | $13M | |
| Stock-based Comp | · | · | · | · | · | · | · | · | · | · | · | $17M | |
| Deferred Tax | $64.0K | $-10.0K | $-140.0K | $3M | $-102.0K | $-36.0K | $-21.0K | $93.0K | $35.0K | $-115.0K | $-22.0K | $-31.0K | |
| Other Non-cash | · | $-61M | $77M | $49M | $98M | $119M | $101M | $28M | $4M | · | · | · | |
| Operating Cash Flow | $-209M | $-176M | $-193M | $-304M | $-413M | $-313M | $-329M | $718M | $-80M | $-117M | $-73M | $-142M | |
| CapEx | $171.0K | $1M | $865.0K | $6M | $15M | $7M | $26M | $14M | $10M | $6M | $11M | $10M | |
| Investing Cash Flow | $-1M | $143M | $140M | $366M | $203M | $496M | $207M | $-1.38B | $-29M | $-82M | · | · | |
| Stock Repurchased | $0 | $3M | $0 | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $0 | $-3M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $181M | $42M | $30.0K | $2M | $36M | $-80M | $23M | $852M | $54M | $204M | · | · | |
| Net Change in Cash | $-29M | $9M | $-53M | $63M | $-174M | $103M | $-99M | $190M | $-55M | $4M | $43M | $-27M | |
| Taxes Paid | $-195.0K | $76.0K | $3M | $272.0K | $325.0K | $539.0K | $555.0K | $618.0K | $556.0K | $757.0K | $860.0K | $964.0K | |
| Free Cash Flow | $-209M | $-177M | $-193M | $-310M | $-428M | $-321M | $-355M | $704M | $-90M | $-123M | $-84M | · | |
| Levered FCF | · | · | · | $-310M | $-428M | $-327M | $-376M | $682M | $-112M | $-146M | $-103M | · |
Redditività
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% | -278.0% | -383.9% | 57.6% | -19.4% | -68.2% | -12.7% | · | |
| Net Margin | -297.1% | -120.9% | -306.3% | -400.0% | -514.0% | -290.6% | -384.5% | 57.1% | -31.4% | -92.8% | -35.2% | · | |
| Pretax Margin | -297.3% | -121.1% | -306.5% | -396.5% | -513.5% | -290.3% | -383.9% | 57.2% | -31.2% | -92.3% | -35.0% | · | |
| EBITDA Margin | -253.7% | -102.7% | -284.8% | -395.4% | -425.0% | -269.8% | -374.3% | 58.4% | -15.3% | -68.2% | -12.7% | · | |
| ROA | -56.2% | -33.9% | -49.8% | -40.3% | -39.5% | -25.3% | -21.3% | 51.2% | -17.9% | -28.8% | -17.2% | · | |
| ROE | -500.1% | -217.0% | -190.2% | -94.5% | -70.7% | -39.5% | -30.4% | 38.9% | -109.9% | -324.7% | -379.7% | · | |
| ROIC | -155.8% | -172.9% | -201.2% | -103.5% | -65.7% | -39.5% | -31.4% | 40.0% | -68.3% | -128.8% | -459.7% | · |
Liquidità e Solvibilità
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.0 | 4.3 | 6.5 | 8.0 | 9.3 | 9.8 | 4.0 | 17.5 | 5.8 | 5.9 | 5.7 | · | |
| Quick Ratio | 0.3 | 0.7 | 0.7 | 1.4 | 0.6 | 2.1 | 0.4 | 2.9 | 5.4 | 5.6 | 5.4 | · | |
| Interest Coverage | · | · | · | · | · | -62.1 | -20.6 | 31.9 | -2.7 | -5.0 | -1.6 | · |
Efficienza
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.9 | 0.6 | 0.3 | 0.5 | · | |
| Inventory Turnover | · | 3.8 | 1.9 | 1.2 | 1.6 | 1.4 | 1.8 | 2.2 | 2.8 | 2.7 | 2.8 | · | |
| Receivables Turnover | · | 163.4 | 25.1 | 6.5 | 3.3 | 4.0 | 2.9 | 49.5 | 29.7 | 9.3 | 19.6 | · |
Per Azione
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $4.41 | $0.33 | $0.68 | $1.94 | $3.66 | $5.98 | $7.96 | $9.90 | $0.55 | $0.58 | $0.05 | · | |
| Revenue / Share | $3.27 | $0.48 | $0.47 | $0.49 | $0.56 | $0.86 | $0.66 | $6.63 | · | · | · | · | |
| Cash Flow / Share | $-12.36 | $-0.85 | $-1.01 | $-1.62 | $-2.25 | $-1.75 | $-1.88 | $3.99 | · | · | · | · | |
| Cash / Share | $0.74 | $0.24 | $0.18 | $0.47 | $0.14 | $1.10 | $0.55 | $1.12 | $0.03 | $0.39 | $0.41 | · | |
| EPS (TTM) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $3.78 | $-0.62 | $-1.10 | $-0.61 | $-0.45 |
Tassi di Crescita
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -43.9% | 9.2% | -2.1% | -9.7% | -33.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -15.7% | -1.1% | -16.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -18.4% | · | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM)
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $55M | $98M | $90M | $92M | $102M | $153M | $115M | $1.19B | $308M | $165M | $231M | $201M | |
| Net Income TTM | $-164M | $-119M | $-276M | $-368M | $-524M | $-444M | $-441M | $681M | $-97M | $-154M | $-81M | $-54M | |
| Market Cap | $862M | $2.59B | $1.61B | $6.39B | $37.59B | $45.92B | $57.16B | $85.56B | $142.90B | $28.20B | $34.19B | · | |
| P/E | -4.3 | -1.6 | -5.8 | -17.2 | -70.9 | -102.4 | -128.5 | 130.4 | -1444.8 | -167.3 | -414.3 | -516.7 | |
| P/S | 15.6 | 26.3 | 17.8 | 69.4 | 368.8 | 300.3 | 498.7 | 71.7 | 464.4 | 170.5 | 148.2 | · | |
| P/B | 9.6 | 42.7 | 12.3 | 17.4 | 55.3 | 42.6 | 40.7 | 49.8 | 1627.1 | 320.0 | 5318.8 | · | |
| P / Tangible Book | 9.6 | 42.7 | 12.3 | 22.0 | 62.3 | 45.9 | · | · | · | · | · | · | |
| P / Cash Flow | -4.1 | -14.7 | -8.3 | -21.0 | -91.1 | -146.6 | -173.9 | 119.1 | -1777.1 | -241.0 | -467.9 | · | |
| P / FCF | -4.1 | -14.6 | -8.3 | -20.6 | -87.9 | -143.3 | -161.0 | 121.5 | -1586.2 | -228.5 | -405.7 | · | |
| Earnings Yield | -23.0% | -62.2% | -17.3% | -5.8% | -1.4% | -0.98% | -0.78% | 0.77% | -0.07% | -0.60% | -0.24% | -0.19% |
Conto Economico
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $11M | $22M | $12M | $11M | $10M | $29M | $24M | $23M | $22M | $24M | $24M | $20M | $22M | $22M | $24M | |
| Cost of Revenue | · | · | $0 | $0 | $0 | $0 | $8M | $4M | $10M | $9M | $7M | $12M | $7M | $7M | $6M | $5M | |
| R&D Expense | $39M | $36M | $30M | $27M | $30M | $30M | $29M | $35M | $30M | $27M | $30M | $24M | $30M | $30M | $35M | $34M | |
| SG&A Expense | $13M | $13M | $11M | $16M | $17M | $24M | $17M | $19M | $21M | $20M | $17M | $21M | $18M | $21M | $22M | $23M | |
| Operating Expenses | $52M | $50M | $49M | $43M | $47M | $55M | $15M | $58M | $73M | $57M | $57M | $69M | $71M | $156M | $74M | $78M | |
| Operating Income | $-42M | $-39M | $-28M | $-32M | $-36M | $-45M | $14M | $-34M | $-50M | $-35M | $-34M | $-45M | $-51M | $-135M | $-52M | $-54M | |
| Interest Income | $9M | $4M | $3M | $3M | $2M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $5M | $4M | · | · | |
| Other Non-op | $-100.0K | $-336.0K | $-44.0K | $-121.0K | $260.0K | $266.0K | $-135.0K | $-120.0K | $-36.0K | $-99.0K | $-6M | $-335.0K | $736.0K | $-301.0K | $-4M | $2M | |
| Pretax Income | $-40M | $-43M | $-43M | $-35M | $-39M | $-46M | $7M | $-37M | $-52M | $-37M | $-42M | $-46M | $-51M | $-137M | $-57M | $-59M | |
| Income Tax | $2.0K | $64.0K | $31.0K | $-33.0K | $-188.0K | $52.0K | $-259.0K | $9.0K | $46.0K | $-35.0K | $-29.0K | $-61.0K | $-47.0K | $-63.0K | $3M | $-155.0K | |
| Net Income | $-41M | $-45M | $-36M | $-36M | $-42M | $-51M | $7M | $-37M | $-52M | $-37M | $-42M | $-46M | $-51M | $-137M | $-60M | $-59M | |
| EPS (Basic) | $-1.23 | $-1.82 | $-4.67 | $-1.87 | $-2.95 | $-3.62 | $-2.07 | $-2.66 | $-3.76 | $-0.19 | $-0.21 | $-0.24 | $-0.27 | $-0.73 | $-0.32 | $-0.31 | |
| EPS (Diluted) | $-1.23 | $-1.82 | $-4.67 | $-1.87 | $-2.95 | $-3.62 | $-2.07 | $-2.66 | $-3.76 | $-0.19 | $-0.21 | $-0.24 | $-0.27 | $-0.73 | $-0.32 | $-0.31 | |
| Shares (Basic) | 33,054,865 | 24,736,066 | · | 18,946,559 | 14,087,307 | 14,063,402 | · | 13,949,851 | 13,921,378 | 194,746,000 | · | 190,406,000 | 189,656,000 | 188,875,000 | · | 187,641,000 | |
| Shares (Diluted) | 33,054,865 | 24,736,066 | · | 18,946,559 | 14,087,307 | 14,063,402 | · | 13,949,851 | 13,921,378 | 194,746,000 | · | 190,406,000 | 189,656,000 | 188,875,000 | · | 187,641,000 | |
| EBITDA | $-42M | $-39M | · | $-32M | $-36M | $-45M | · | $-34M | $-50M | $-35M | · | $-45M | $-51M | $-135M | · | $-54M |
Stato Patrimoniale
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $39M | $150M | $15M | $41M | $43M | $39M | $44M | $30M | $28M | $49M | $35M | $65M | $51M | $77M | $88M | $106M | |
| Receivables | · | · | · | · | · | · | · | $0 | $1M | $4M | $1M | $2M | $1M | $3M | $6M | $12M | |
| Inventory | · | · | $0 | · | · | · | $0 | $0 | $14M | $16M | $16M | $15M | $21M | $20M | $19M | $19M | |
| Other Current Assets | $55M | $20M | $21M | $11M | $11M | $11M | $6M | $9M | $8M | $11M | $10M | $9M | $10M | $11M | $16M | $23M | |
| Current Assets | $739M | $589M | $266M | $281M | $187M | $230M | $261M | $286M | $295M | $320M | $331M | $399M | $441M | $491M | $546M | $599M | |
| PP&E (Net) | · | · | $2M | $3M | $3M | $3M | $3M | $4M | $15M | $17M | $19M | $20M | $23M | $27M | $32M | $37M | |
| Accum. Depreciation | · | · | · | · | · | · | · | $16M | $88M | · | $87M | $88M | $108M | $111M | $125M | · | |
| Goodwill | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $77M | $77M | |
| Other Non-current Assets | $17M | $11M | $6M | $5M | $5M | $5M | $5M | $5M | $4M | $5M | $5M | $5M | $2M | $1M | $2M | $2M | |
| Total Assets | $1.10B | $763M | $280M | $301M | $208M | $256M | $304M | $308M | $343M | $396M | $398M | $442M | $494M | $562M | $711M | $781M | |
| Accounts Payable | $25M | $10M | $11M | $16M | $14M | $18M | $12M | $9M | $6M | $9M | $10M | $3M | $3M | $4M | $13M | $5M | |
| Accrued Liabilities | $23M | $25M | $22M | $29M | $35M | $31M | $30M | $32M | $30M | $24M | $22M | $30M | $29M | $37M | $37M | · | |
| Current Liabilities | $71M | $58M | $54M | $66M | $71M | $71M | $61M | $68M | $57M | $52M | $51M | $52M | $51M | $60M | $68M | $84M | |
| Capital Leases | $56M | $61M | $65M | $70M | $74M | $78M | $83M | $87M | $91M | $95M | $99M | $102M | $106M | $109M | $113M | $116M | |
| Other Non-current Liabilities | $8M | $8M | $9M | $5M | $6M | $7M | $7M | $7M | $8M | $4M | $5M | $5M | $5M | $6M | $8M | $3M | |
| Total Liabilities | $192M | $187M | $191M | $216M | $232M | $243M | $243M | $259M | $264M | $269M | $267M | $283M | $297M | $321M | $344M | $369M | |
| Common Stock | $3.0K | $3.0K | $2.0K | $2.0K | $1.0K | $19.0K | $1.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | |
| Retained Earnings | $-3.85B | $-3.81B | $-3.76B | $-3.72B | $-3.69B | $-3.65B | $-3.60B | $-3.60B | $-3.57B | $-3.51B | $-3.48B | $-3.44B | $-3.39B | $-3.34B | $-3.20B | $-3.14B | |
| Treasury Stock | · | · | · | $0 | $3M | $3M | $3M | $3M | $3M | $3M | · | · | · | · | · | · | |
| AOCI | $-2M | $-1M | $17.0K | $56.0K | $-14.0K | $39.0K | $61.0K | $355.0K | $-494.0K | $-403.0K | $80.0K | $-6M | $-6M | $-6M | $-7M | $-8M | |
| Stockholders' Equity | $903M | $576M | $90M | $85M | $-24M | $14M | $61M | $49M | $80M | $127M | $131M | $159M | $197M | $241M | $367M | $412M | |
| Liabilities + Equity | $1.10B | $763M | $280M | $301M | $208M | $256M | $304M | $308M | $343M | $396M | $398M | $442M | $494M | $562M | $711M | $781M | |
| Shares Outstanding | 20,378,832 | 20,378,832 | 20,378,832 | 19,652,513 | 12,457,252 | 186,103,000 | 12,385,001 | 184,458,000 | 184,061,000 | 183,624,000 | 191,384,000 | 190,771,000 | 190,119,000 | 189,235,000 | 188,560,000 | 187,954,000 |
Flusso di cassa
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $156.0K | $151.0K | $190.0K | $196.0K | $214.0K | $426.0K | $332.0K | $993.0K | $1M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | |
| Deferred Tax | · | · | · | · | · | · | $2.0K | $-31.0K | $57.0K | $-38.0K | $2M | $-15.0K | $-27.0K | $-2M | $3M | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $17M | |
| Operating Cash Flow | $-76M | $-44M | $-65M | $-49M | $-46M | $-49M | $-46M | $-44M | $-38M | $-48M | $-47M | $-42M | $-52M | $-52M | $-58M | $-83M | |
| CapEx | $94.0K | $18.0K | $18.0K | $114.0K | $37.0K | $2.0K | $459.0K | $666.0K | $186.0K | $157.0K | $237.0K | $33.0K | $162.0K | $433.0K | $512.0K | $181.0K | |
| Investing Cash Flow | $-399M | $-351M | $372.0K | $-95M | $50M | $44M | $60M | $46M | $17M | $19M | $17M | $56M | $25M | $41M | $40M | $111M | |
| Stock Repurchased | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3M | $0 | $0 | $0 | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $-3M | · | · | · | · | · | · | |
| Financing Cash Flow | $365M | $530M | $39M | $142M | $211.0K | $7.0K | $83.0K | $13.0K | $19.0K | $42M | $12.0K | $0 | $18.0K | $0 | $103.0K | $0 | |
| Net Change in Cash | $-110M | $134M | $-26M | $-2M | $4M | $-5M | $14M | $2M | $-21M | $13M | $-30M | $14M | $-26M | $-11M | $-18M | $28M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | $0 | $0 | · | · | $272.0K | $-85.0K | |
| Free Cash Flow | · | $-44M | · | · | · | $-49M | · | · | · | $-48M | · | · | · | $-52M | · | · |
Redditività
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -417.9% | -359.6% | · | -268.6% | -324.2% | -425.8% | · | -142.4% | -211.9% | -163.7% | · | -185.8% | -246.8% | -623.8% | · | -229.9% | |
| Net Margin | -401.0% | -413.4% | · | -301.3% | -372.2% | -486.4% | · | -153.6% | -222.9% | -170.1% | · | -189.8% | -249.4% | -634.5% | · | -249.9% | |
| Pretax Margin | -397.8% | -396.7% | · | -297.0% | -352.5% | -443.3% | · | -153.6% | -222.7% | -170.2% | · | -190.1% | -249.6% | -634.8% | · | -250.6% | |
| EBITDA Margin | -417.9% | -359.6% | · | -268.6% | -324.2% | -425.8% | · | -142.4% | -211.9% | -163.7% | · | -185.8% | -246.8% | -623.8% | · | -229.9% | |
| ROA | -6.2% | -8.8% | · | -11.7% | -15.1% | -15.6% | · | -9.9% | -12.5% | -7.7% | · | -7.5% | -7.5% | -17.3% | · | -5.7% | |
| ROE | -9.2% | -15.2% | · | -53.0% | -150.0% | -72.5% | · | -35.6% | -37.9% | -20.0% | · | -16.0% | -15.6% | -32.3% | · | -9.7% | |
| ROIC | -4.7% | -6.8% | · | -37.2% | 148.9% | -324.5% | · | -70.3% | -62.5% | -27.9% | · | -28.1% | -25.7% | -55.9% | · | -13.1% |
Liquidità e Solvibilità
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.4 | 10.2 | · | 4.2 | 2.6 | 3.2 | · | 4.2 | 5.1 | 6.1 | · | 7.7 | 8.7 | 8.2 | · | 7.1 | |
| Quick Ratio | 0.6 | 2.6 | · | 0.6 | 0.6 | 0.5 | · | 0.4 | 0.5 | 1.0 | · | 1.3 | 1.0 | 1.3 | · | 1.4 |
Efficienza
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | · | · | · | · | · | · | · | 0.6 | 0.6 | 0.5 | · | 0.7 | 0.4 | 0.4 | · | 0.3 | |
| Receivables Turnover | · | · | · | · | · | · | · | 21.9 | 18.6 | 6.5 | · | 3.5 | 3.6 | 1.3 | · | 1.2 |
Per Azione
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $44.32 | $28.28 | · | $4.33 | $-1.94 | $0.07 | · | $0.27 | $0.43 | $0.69 | · | $0.84 | $1.04 | $1.27 | · | $2.19 | |
| Revenue / Share | $0.31 | $0.44 | · | $0.62 | $0.79 | $0.05 | · | $0.12 | $0.11 | $0.11 | · | $0.13 | $0.11 | $0.11 | · | $0.13 | |
| Cash Flow / Share | · | $-1.79 | · | · | · | $-0.23 | · | · | · | $-0.25 | · | · | · | $-0.27 | · | · | |
| Cash / Share | $1.93 | $7.34 | · | $2.09 | $3.45 | $0.21 | · | $0.16 | $0.15 | $0.26 | · | $0.34 | $0.27 | $0.41 | · | $0.56 | |
| EPS (TTM) | $-9.59 | $-11.31 | · | $-10.51 | $-11.30 | $-12.11 | · | $-6.82 | $-4.40 | $-0.91 | · | $-1.56 | $-1.63 | $-2.21 | · | $-2.44 |
Valutazione (TTM)
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $55M | $56M | · | $63M | $75M | $87M | · | $93M | $93M | $90M | · | $88M | $88M | $89M | · | $95M | |
| Net Income TTM | $-157M | $-158M | · | $-121M | $-122M | $-133M | · | $-168M | $-177M | $-176M | · | $-294M | $-307M | $-415M | · | $-454M | |
| Market Cap | $1.42B | $1.47B | · | $1.12B | $322M | $1.90B | · | $3.60B | $3.42B | $2.56B | · | $1.72B | $1.65B | $1.99B | · | $9.02B | |
| P/E | -7.3 | -6.4 | · | -5.4 | -2.3 | -0.8 | · | -2.9 | -4.2 | -15.3 | · | -5.8 | -5.3 | -4.8 | · | -19.7 | |
| P/S | 26.1 | 26.4 | · | 17.9 | 4.3 | 21.8 | · | 38.6 | 36.8 | 28.4 | · | 19.5 | 18.9 | 22.4 | · | 94.9 | |
| P/B | 1.6 | 2.5 | · | 13.1 | -13.3 | 138.2 | · | 73.6 | 43.0 | 20.2 | · | 10.8 | 8.4 | 8.2 | · | 21.9 | |
| P / Tangible Book | 1.6 | 2.5 | · | 13.1 | · | 138.2 | · | 73.6 | 43.0 | 20.2 | · | 10.8 | 8.4 | 8.2 | · | 26.9 | |
| P / Cash Flow | · | -33.1 | · | · | · | -38.7 | · | · | · | -53.5 | · | · | · | -38.3 | · | · | |
| Earnings Yield | -13.7% | -15.7% | · | -18.5% | -43.7% | -118.7% | · | -35.0% | -23.7% | -6.5% | · | -17.3% | -18.7% | -21.1% | · | -5.1% |
Periodo più recente a sinistra · valori nulli mostrati come ·
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ricavi | $55M | $98M | $90M | $92M | $102M |
| Margine Operativo % | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% |
| Utile netto | $-164M | $-119M | $-276M | $-368M | $-524M |
| EPS Diluito | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Rapporto corrente | 5.0 | 4.3 | 6.5 | 8.0 | 9.3 |
| Quick Ratio | 0.3 | 0.7 | 0.7 | 1.4 | 0.6 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flusso di cassa libero | $-209M | $-177M | $-193M | $-310M | $-428M |
Proprietari istituzionali (13F) 267 filer · $2.7B totale · Aggiornato al 30 Settembre 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Detentori
267
Valore detenuto
$2.7B
Nuove posizioni
78
Posizioni chiuse
42
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 78 (+2 vs trimestre precedente) | 42 (+11 vs trimestre precedente) | 105 (+27 vs trimestre precedente) | 44 (-6 vs trimestre precedente) | +10.6M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| FMR LLC | $353.791.520 | 5.067.920 | 13,17% | Azioni |
| Two Seas Capital LP | $215.868.856 | 3.092.234 | 8,04% | Azioni |
| BlackRock, Inc. | $205.370.620 | 2.941.851 | 7,64% | Azioni |
| BVF INC/IL | $166.920.946 | 2.391.075 | 6,21% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $104.495.029 | 1.496.849 | 3,89% | Azioni |
| TWO SIGMA INVESTMENTS, LP | $83.911.899 | 1.202.004 | 3,12% | Azioni |
| Vestal Point Capital, LP | $69.810.000 | 1.000.000 | 2,60% | Azioni |
| MORGAN STANLEY | $65.381.263 | 936.560 | 2,43% | Azioni |
| STATE STREET CORP | $63.504.691 | 909.679 | 2,36% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $61.536.312 | 881.306 | 2,29% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $57.502.497 | 823.700 | 2,14% | Opzione Call |
| Prosight Management, LP | $56.546.100 | 810.000 | 2,10% | Azioni |
| ARMISTICE CAPITAL, LLC | $50.542.440 | 724.000 | 1,88% | Azioni |
| VANGUARD GROUP INC | $43.425.322 | 1.027.089 | 1,62% | Azioni |
| GILDER GAGNON HOWE & CO LLC | $41.946.944 | 600.873 | 1,56% | Azioni |
| MILLENNIUM MANAGEMENT LLC | $33.377.557 | 478.120 | 1,24% | Azioni |
| BRAIDWELL LP | $33.063.203 | 473.617 | 1,23% | Azioni |
| Sofinnova Investments, Inc. | $32.933.775 | 471.763 | 1,23% | Azioni |
| Woodline Partners LP | $32.871.784 | 470.875 | 1,22% | Azioni |
| ORBIMED ADVISORS LLC | $32.485.804 | 465.346 | 1,21% | Azioni |
| UBS Group AG | $29.906.604 | 428.400 | 1,11% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $27.540.045 | 394.500 | 1,03% | Opzione Put |
| EMERALD ADVISERS, LLC | $27.236.930 | 390.158 | 1,01% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $24.331.577 | 348.540 | 0,91% | Azioni |
| DAFNA Capital Management LLC | $22.226.108 | 318.380 | 0,83% | Azioni |
| NORTHERN TRUST CORP | $21.538.548 | 308.531 | 0,80% | Azioni |
| Deep Track Capital, LP | $20.943.000 | 300.000 | 0,78% | Azioni |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $19.893.826 | 284.971 | 0,74% | Azioni |
| 22NW, LP | $19.624.638 | 281.115 | 0,73% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19.475.384 | 278.977 | 0,72% | Azioni |
| PRIMECAP MANAGEMENT CO/CA/ | $19.047.658 | 272.850 | 0,71% | Azioni |
| BARCLAYS PLC | $18.315.491 | 262.362 | 0,68% | Azioni |
| Nearwater Capital Markets, Ltd | $18.255.315 | 261.500 | 0,68% | Azioni |
| EMERALD MUTUAL FUND ADVISERS TRUST | $17.842.528 | 255.587 | 0,66% | Azioni |
| ADAR1 Capital Management, LLC | $17.046.485 | 244.184 | 0,63% | Azioni |
| Creek Drive Management Group LLC | $16.963.830 | 243.000 | 0,63% | Azioni |
| SEVEN GRAND MANAGERS, LLC | $16.754.400 | 240.000 | 0,62% | Azioni |
| DEUTSCHE BANK AG\ | $16.742.602 | 239.831 | 0,62% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $16.724.731 | 239.575 | 0,62% | Azioni |
| GOLDMAN SACHS GROUP INC | $15.950.887 | 228.490 | 0,59% | Azioni |
| NORGES BANK | $15.030.093 | 215.300 | 0,56% | Azioni |
| Bronte Capital Management Pty Ltd. | $13.852.678 | 198.434 | 0,52% | Azioni |
| TWO SIGMA ADVISERS, LP | $13.039.744 | 308.414 | 0,49% | Azioni |
| CITADEL ADVISORS LLC | $12.251.655 | 175.500 | 0,46% | Opzione Put |
| GREAT POINT PARTNERS LLC | $12.216.750 | 175.000 | 0,45% | Azioni |
| Caption Management, LLC | $11.944.491 | 171.100 | 0,44% | Opzione Call |
| MILLENNIUM MANAGEMENT LLC | $11.867.700 | 170.000 | 0,44% | Opzione Call |
| AMERIPRISE FINANCIAL INC | $11.584.330 | 165.941 | 0,43% | Azioni |
| CITADEL ADVISORS LLC | $11.434.878 | 163.800 | 0,43% | Opzione Call |
| CITADEL ADVISORS LLC | $11.151.938 | 159.747 | 0,42% | Azioni |
Attivisti e proprietari del 5%+ 1 partecipazione
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| Nektar Therapeutics ( | 22 Agosto 2005 | · | Deposito iniziale | M&A / vendita | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insider aziendali 40 insider · 20 dirigenti · 18 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Howard W Robin | President & CEO | 18 Agosto 2026 S | 54.627 | 0 | 8 | $-1.424.905 |
| Jillian B. Thomsen | Chief Financial Officer | 16 Febbraio 2023 S | 313.497 | 0 | 0 | $0 |
| Gil M Labrucherie | SVP, COO & CFO | 16 Maggio 2022 S | 312.905 | 0 | 0 | $0 |
| Timothy Harkness | SVP & Chief Financial Officer | 23 Agosto 2007 A | · | 0 | 0 | $0 |
| Louis Drapeau | Sr. VP Finance, CFO | 14 Maggio 2007 A | 6.000 | 0 | 0 | $0 |
| Milton J Harris | President of Nektar AL | 04 Marzo 2004 S | 743.904 | 0 | 0 | $0 |
| John Nicholson | SVP & Chief Operating Officer | 16 Agosto 2019 S | 162.759 | 0 | 0 | $0 |
| Bharat M Chowrira | Chief Operating Officer | 01 Febbraio 2010 A | · | 0 | 0 | $0 |
| Jonathan Zalevsky | Chief R&D Officer | 18 Agosto 2026 S | 9.570 | 0 | 7 | $-974.184 |
| Mark Andrew Wilson | Chief Legal Officer | 21 Novembre 2025 A | 21.585 | 0 | 1 | $-34.196 |
| John Northcott | SVP & Chief Commercial Officer | 16 Maggio 2022 S | 223.210 | 0 | 0 | $0 |
| Stephen K Doberstein | SVP & Chief Scientific Officer | 05 Settembre 2019 P | 107.668 | 0 | 0 | $0 |
| Maninder Hora | SVP Pharma Dev & Mfg Ops | 16 Maggio 2019 S | 94.694 | 0 | 0 | $0 |
| Ivan P. Gergel | SVP & Chief Medical Officer | 15 Novembre 2017 A | 56.553 | 0 | 0 | $0 |
| Robert Medve | SVP & Chief Medical Officer | 05 Febbraio 2014 A | · | 0 | 0 | $0 |
| Rinko Ghosh | Chief Business Officer | 06 Febbraio 2013 A | 9.753 | 0 | 0 | $0 |
| Randall W Moreadith | SVP Drug Development | 23 Febbraio 2009 A | · | 0 | 0 | $0 |
| John Stuart Patton | Chief Scientific Officer | 14 Novembre 2008 M | 313.880 | 0 | 0 | $0 |
| Nevan C Elam | SVP & Head of Pulmonary Bus | 25 Febbraio 2008 A | 1.400 | 0 | 0 | $0 |
| David Johnston | SVP, Research & Development | 14 Maggio 2007 D | 6.600 | 0 | 0 | $0 |
| Diana Brainard | Direttore | 23 Settembre 2026 A | 3.904 | 0 | 0 | $0 |
| Jeffrey Robert Ajer | Direttore | 23 Settembre 2026 A | 4.277 | 0 | 0 | $0 |
| Robert Chess | Direttore | 23 Settembre 2026 A | 19.019 | 0 | 0 | $0 |
| Scott R Greer | Direttore | 23 Settembre 2026 A | 22.239 | 0 | 0 | $0 |
| Roy A Whitfield | Direttore | 23 Settembre 2026 A | 16.417 | 0 | 0 | $0 |
| Myriam Curet | Direttore | 19 Settembre 2023 A | 27.418 | 0 | 0 | $0 |
| Karin Eastham | Direttore | 16 Settembre 2022 A | 23.233 | 0 | 0 | $0 |
| Lutz Lingnau | Direttore | 22 Settembre 2020 A | 35.800 | 0 | 0 | $0 |
| Christopher A Kuebler | Direttore | 27 Settembre 2018 A | 45.250 | 0 | 0 | $0 |
| Dennis L Winger | Direttore | 21 Agosto 2018 M | 42.750 | 0 | 0 | $0 |
| Joseph J Krivulka | Direttore | 19 Settembre 2017 A | 82.000 | 0 | 0 | $0 |
| Susan Wang | Direttore | 20 Novembre 2015 M | 20.000 | 0 | 0 | $0 |
| BROWN MICHAEL A/CA | Direttore | 15 Settembre 2009 A | 10.000 | 0 | 0 | $0 |
| Hoyoung Huh | Direttore | 02 Dicembre 2008 A | · | 0 | 0 | $0 |
| Irwin Lerner | Direttore | 02 Dicembre 2008 A | 10.000 | 0 | 0 | $0 |
| James B Glavin | Direttore | 04 Settembre 2003 A | · | 0 | 0 | $0 |
| Masuoka K. Lorianne | · | 08 Febbraio 2011 A | · | 0 | 0 | $0 |
| Ajit Gill | President & CEO | 23 Marzo 2006 S | 87.991 | 0 | 0 | $0 |
| Ajay Bansal | · | 10 Marzo 2006 S | 5.166 | 0 | 0 | $0 |
| Melvin Perelman | · | 02 Settembre 2004 A | · | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Proprietà ETF Posseduti da 25 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| SPIT · RBB Fund, Inc. | 2,05% | 9.695 NS | 31 Luglio 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1,42% | 4.138 NS | 31 Luglio 2026 | N-PORT |
| BBC · ETFis Series Trust I | 0,80% | 5.234 NS | 31 Luglio 2026 | N-PORT |
| IHE · iShares Trust | 0,55% | 125.055 SH | 11 Settembre 2026 | Giornaliero |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,44% | 1.670 SH | 01 Ottobre 2026 | Giornaliero |
| IWO · iShares Trust | 0,14% | 289.334 SH | 11 Settembre 2026 | Giornaliero |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,13% | 33.135 SH | 19 Agosto 2026 | Giornaliero |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,08% | 37.498 SH | 01 Ottobre 2026 | Giornaliero |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,08% | 7.900 NS | 31 Luglio 2026 | N-PORT |
| IWM · iShares Trust | 0,08% | 879.755 SH | 11 Settembre 2026 | Giornaliero |
| RSSL · Global X Funds | 0,08% | 16.502 NS | 31 Luglio 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 198.365 SH | 19 Agosto 2026 | Giornaliero |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 14.592 NS | 31 Luglio 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 387.471 SH | 19 Agosto 2026 | Giornaliero |
| VHT · VANGUARD WORLD FUND | 0,03% | 92.340 SH | 19 Agosto 2026 | Giornaliero |
| WSML · iShares Trust | 0,02% | 1.906 SH | 11 Settembre 2026 | Giornaliero |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 3.096 SH | 19 Agosto 2026 | Giornaliero |
| ITOT · iShares Trust | 0,00% | 48.120 SH | 11 Settembre 2026 | Giornaliero |
| IWV · iShares Trust | 0,00% | 9.239 SH | 11 Settembre 2026 | Giornaliero |
| TILT · FlexShares Trust | 0,00% | 810 NS | 31 Luglio 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.075.430 SH | 19 Agosto 2026 | Giornaliero |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2.837 SH | 19 Agosto 2026 | Giornaliero |
| IWN · iShares Trust | · | 32.591 SH | 11 Settembre 2026 | Giornaliero |
| ISCB · iShares Trust | · | 1.294 SH | 11 Settembre 2026 | Giornaliero |
| ISCV · iShares Trust | · | 6.414 SH | 11 Settembre 2026 | Giornaliero |
NKTR Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
rating · 18 analisti
COMPRA
Target mediano
$150.50
+245,3%
7 38,9%
Acquisto forte
8 44,4%
Compra
3 16,7%
Mantieni
0 0,0%
Vendi
0 0,0%
Vendita forte
Target Price a 12 Mesi
10 analisti · 2026-09-27Target medio $141.40 +224,5%
← Sotto tutti i target
Prezzo attuale $43.58
Basso$50.00
Media$141.40
Alto$192.00
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| NKTR | $862M | -4.3 | -43.9% | -297.1% | -500.1% | · |
| ANIP | $1.78B | 23.8 | 43.8% | 8.9% | 16.6% | · |
| ETON | $457M | · | 104.9% | -5.8% | -18.4% | 53.5% |
| RAPP | $1.45B | -10.6 | · | · | -29.8% | · |
| OCUL | $2.62B | -8.5 | -18.5% | -511.9% | -55.4% | · |
| PAHC | · | 12.9 | 17.1% | 6.6% | 29.7% | 33.8% |
| INVA | · | 6.1 | 14.7% | · | · | · |
| MAZE | $2.04B | -13.6 | · | · | -598.9% | · |
| XERS | $1.30B | · | 43.7% | 0.19% | -19.7% | · |
| KARD | · | · | · | · | · | · |
| OMER | $1.23B | -343.6 | · | · | 1.9% | · |
Ultime notizie Notizie recenti che menzionano questa società
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Fonte: SEC 10-Q depositato Ago 14, 2026